DR. STEPHANIE HOYER PINCUS, M.D.
Osteopathic Medicine at Bailey Ave, Buffalo, NY

2011022, Sep 15, 2011

Sep 11, 2008

12/677381

Ravindra K. Pandey - Williamsville NY, US
Suresh Pandey - Buffalo NY, US
Lalit Goswami - Columbia MO, US
Allan Oseroff - Buffalo NY, US
Shipra Dubey - Williamsville NY, US
Munawwar Sajjad - Clarence Center NY, US
Stephanie Pincus - Buffalo NY, US

HEALTH RESEARCH, INC. - Buffalo NY
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK - Amherst NY

A61K 51/04, A61K 49/00, A61K 31/30, A61K 31/409, A61K 38/12, A61K 31/437, A61K 31/506, A61P 35/00, A61P 43/00

424 111, 424 91, 514499, 514410, 514 199, 514279, 514275

A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is C, F, Cu, I, Tc, In or GdIII and its method of use for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors. Preferably the photosensitizer is a tumor avid tetrapyrollic photosensitizer, e.g. a porphyrin, chlorin or bacteriochlorin, e.g. pheophorbides and pyropheophorbides. Such conjugates have extreme tumor avidity and can be used to inhibit or completely destroy the tumor by light absoption. The integrin is usually αvβ3, α5β1, αvβ5, α4β1, or α2β1. Preferably, the antagonist is an RGD peptide or another antagonist that may be synthetic such as a 4-{2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethyloxy}-benzoyl]amino-2-(S)-amino-ethyl-sulfonylamino group. Such compounds provide tumor avidity and imaging ability thus permitting selective and clear tumor imaging.

2011028, Nov 24, 2011

Feb 19, 2009

12/918232

Ravindra K. Pandey - Williamsville NY, US
Lalit N. Goswami - Columbia MO, US
Allan Oseroff - Buffalo NY, US
Stephanie Pincus - Buffalo NY, US
Janet Morgan - Buffalo NY, US
Paras N. Prasad - Williamsville NY, US
Earl J. Bergey - South Dayton NY, US

The Research Foundation on State University of NY - Amherst NY
Health Research, Inc. - Buffalo NY

C08G 77/38, C08F 130/08, C08G 77/388, B82Y 5/00

525 541, 525474, 525 542, 5253265, 977773, 977788, 977906, 977927, 977897, 977930, 977928

A nanoparticle including a polysiloxane base having an exterior surface and having a photosensitizer at least partly exposed at its exterior surface, said photosensitizer being secured to the exterior surface by loading the photosensitizer onto the surface after formation of the polysiloxane base of the nanoparticle. The nanoparticle may have tumor targeting moieties and may be post loaded with cyanine dye. The nanoparticle preferably includes post loaded moieties providing at least two of tumor specificity, photodynamic properties and imaging capabilities and the photosensitizer is tagged with a radioisotope. A method for preparation of the nanoparticle is also provided.

2010025, Oct 7, 2010

Jun 29, 2007

12/309028

Ravindra K. Pandey - Williamsville NY, US
Allan Oseroff - Buffalo NY, US
Stephanie Pincus - Buffalo NY, US
Janet Morgan - Buffalo NY, US
Xiang Zheng - Quincy MA, US
Weiguo Liu - Snyder NY, US

A61K 31/5377, A61K 31/517, A61K 31/506, A61K 31/4045, A61K 31/409, A61P 35/00

5142345, 5142664, 51425218, 514414, 514410

A method for treating hyperproliferative tissue in a mammal which tissue expresses ABCG2 including the steps of: a) systemically introducing from about 100 to about 1000 mg/kg of body weight of a tyrosine kinase inhibiting compound into the mammal; b) within from about 0.5 to about 24 hours after the introducing in step a) systemically introducing from about 0.05 to about 0.5 μmol per kilogram of body weight of a tumor avid photosensitizing compound, that acts as a substrate for ABC family transport protein, ABCG2 and that has a preferential light absorbance frequency; and c) exposing the hyperproliferative tissue to light at a fluence of from about 50 to about 150 J/cmdelivered at a rate of from about 5 to about 25 mW/cmat the light absorbance frequency. The photosensitizing compound is preferably a tetrapyrollic photosensitizer compound where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pheophorbide including pyropheophorbides, purpurinimide, or bacteriopurpurinimide and derivatives thereof; provided that, the photosensizing compound is not a meso-tetra (3-hydroxyphenyl) derivative, is not a saccharide derivative and is not a hematoporphyrin.

2011026, Oct 27, 2011

Feb 19, 2009

12/918238

Ravindra K. Pandey - Williamsville NY, US
Chao Liu - Barcelona, ES
Mahabeer Dobhal - Amherst NY, US
William Potter - Amherst NY, US
Janet Morgan - Buffalo NY, US
Allan Oseroff - Buffalo NY, US
Stephanie Pincus - Buffalo NY, US

Health Research, Inc. - Buffalo NY

A61N 5/00, A61P 35/00, A61K 51/04, A61K 49/00, C07D 487/22, A61K 49/04

604 20, 540145, 424 942, 424 181, 424 185, 424 189, 424 165, 424 944, 424 91

Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl.6HO to oxidize the D ring and separating the resulting organic layer and drying.

2010029, Nov 18, 2010

Oct 20, 2008

12/738196

William J. Cottrell - Somerville MA, US
Thomas H. Foster - Rochester NY, US
Allan R. Oseroff - Buffalo NY, US
Stephanie H. Pincus - Buffalo NY, US
Tammy Lee - Rochester NY, US

A61N 5/06

607 88

In a first embodiment, there is no monitoring, and instead light is delivered according to a predetermined ‘recipe.’ In a second embodiment, the instrumentation provides a means for making the reflectance measurements during therapy without requiring the brief interruption. This device may therefore allow more accurate measurement of treatment-induced changes to the reflectance measurement. In a third embodiment, an adjustable aperture is used to constrict the area of a treatment beam.

2010018, Jul 22, 2010

Aug 5, 2009

12/462535

Ravindra K. Pandey - Williamsville NY, US
Munawwar Sajjad - Clarence Center NY, US
Suresh Pandey - Chelmsford MA, US
Amy Gryshuk - Livermore CA, US
Allan Oseroff - Buffalo NY, US
Hani A. Nabi - Clarence NY, US
Stephanie Pincus - Buffalo NY, US

Health Research, Inc. - Buffalo NY
The Research Foundation of State University of New York - Amherst NY

C07D 487/22

540145

This invention describes a first report on the synthesis of certain I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy (PDT). The development of tumor imaging or improved photodynamic therapy agent(s) itself represent an important step, but a dual function agent (PET imaging and PDT) provides the potential for diagnostic body scan followed by targeted therapy.